2008•Cancer LettersRequires access

EGFR and VEGFR as potential target for biological therapies in HCC cells

Gianluigi Giannelli, Concetta Sgarra, Letizia Porcelli, Amalia Azzariti, Salvatore Antonaci, Angelo Paradiso

Open publisher page 57 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 57 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Vandetanib, Gefitinib, EGFR inhibitors, Matrix metalloproteinase inhibitor, Cancer research, Protein kinase B, Matrigel, PI3K/AKT/mTOR pathway

Back to paper search Browse research topics Original source

EGFR and VEGFR as potential target for biological therapies in HCC cells — Research Paper | ScholarLens